GlassScriptPhysician profile
Geo Mathew
NPI 1215990205
$20,450.56
in general payments reported to CMS, 2019-2025
33 companies · $5,207 in 2025
The $5,207 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,193 · 2022: $6,548 · 2023: $2,858 · 2024: $3,644 · 2025: $5,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,534.50 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $3,339.08 | 2022-2025 | Omvoh |
| Abbvie INC. | $3,315.90 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,318.86 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,624.46 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $1,247.76 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $1,223.41 | 2024-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $893.46 | 2022-2025 | Ibsrela |
| Celgene Corporation | $816.91 | 2022-2024 | Zeposia |
| Daiichi Sankyo INC. | $781.96 | 2021-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $766.95 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $576.64 | 2021-2025 | Livdelzi, Epclusa |
| Medtronic, INC. | $422.80 | 2023-2025 | Venaseal |
| Madrigal Pharmaceuticals | $364.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $321.65 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $301.60 | 2021-2025 | Ocaliva |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $294.32 | 2022-2025 | Dupixent |
| Genzyme Corporation | $279.15 | 2022-2025 | |
| Braintree Laboratories, INC. | $219.36 | 2021-2023 | Sutab, Suflave |
| E.R. Squibb & Sons, L.L.C. | $208.45 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $161.60 | 2025 | Iqirvo |
| Nevro Corp. | $146.91 | 2023 | Senza |
| Blueprint Medicines Corporation | $139.71 | 2024 | Ayvakit |
| Janssen Scientific Affairs, LLC | $123.95 | 2021 | |
| Redhill Biopharma INC. | $115.54 | 2021-2024 | Talicia |
| Qol Medical, LLC | $103.03 | 2023-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $95.44 | 2021-2024 | Linzess |
| Pfizer INC. | $90.03 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $59.68 | 2023-2024 | Dificid |
| Organon LLC | $25.15 | 2025 | Renflexis, Hadlima |
| Olympus America INC. | $20.67 | 2023 | Single Use Electrosurgical Snare Sd-400 |
| Astellas Pharma US INC | $19.33 | 2023 | Myrbetriq |
| Evoke Pharma, INC. | $16.23 | 2021 | |
| Ethicon US, LLC | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geo Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.